Steroidal compounds have been extensively studied for the treatment of Prostatic Benign Hyperplasia (BPH) and Prostate Cancer, which are the most common prostate diseases in men. In this study we report the synthesis and pharmacological evaluation in vitro as well as in vivo of eight 17β-N-arylcarbamoilandrost-4-en-3-one derivatives (6a-h). In the in vitro experiments we determined the IC50 values for the inhibition of human prostatic 5α-reductase enzyme (5aR) and the antiproliferative effect in human prostate cancer LNCaP cell line. In the in vivo assays we measured the activity of these compounds on different androgen-sensitive tissues of gonadectomized hamsters treated with testosterone. Results from these studies indicate that the novel derivatives present an inhibitory activity in 5aR enzyme (IC50 = 150 to 0.112 nM). Moreover, compounds 6f and 6g exhibit higher antiproliferative effect than commercially available flutamide in LNCaP cells. Additionally, these derivatives decrease the size of the tissues in gonadectomized hamsters.

Synthesis of 17β-N-arylcarbamoylandrost-4-en-3-one derivatives and their in vitro and in vivo effect as potent 5α-reductase inhibitors

250th National Meeting (2015)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.